The FDA has just authorised vaccines ... also said that Novavax' latecomer COVID-19 shot Nuvaxovid, which targets only the original SARS-CoV-2 strain, can be used as a booster for adults ...

Novavax shares are trading lower by 9.8% during Monday's session. Shares of vaccine stocks are trading lower after Moderna issued 2025 revenue guidance below analyst estimates. Next: Access Our ...

Shares of this vaccine maker have returned -13.6% over the past month versus the Zacks S&P 500 composite's +1% change. The Zacks Medical - Biomedical and Genetics industry, to which Novavax ...

Back in November 2023, pharmaphorum travelled to Uppsala, Sweden, for a Novavax press conference, the company celebrating a decade of doing what it does best: vaccines. From COVID-19 to malaria ...

"Today, we announce the beginning of an exciting new chapter for Novavax with the launch of a strategically important partnership with one of the world's leading vaccine companies," NVAX CEO John ...

Novavax (NVAX) ended the recent trading session ... Coming into today, shares of the vaccine maker had lost 5.5% in the past month. In that same time, the Medical sector lost 3.48%, while the ...

Novavax, Inc. (NYSE:NVAX) is a leading biotechnology company dedicated to the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.

shares of this vaccine maker have returned +3.5%, compared to the Zacks S&P 500 composite's +2.1% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which Novavax ...

Shares of Novavax declined after the company reaffirmed full-year revenue and fellow vaccine maker Moderna lowered its guidance. Novavax stock was down 7.3%, to $8.64, on Monday but is up about 89 ...